Noom Acquires Compounding Pharmacy TMC to Expand Into Peptide Therapies
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy in 46 states serving 400+ clinics, offering compounded peptides including sermorelin, GHK-Cu, and oxytocin.
#compounding
15 stories
Utah Physician Indicted for Importing Misbranded Peptides From China; 5,000 Units Seized
A Utah physician was indicted for importing and selling misbranded drugs from China to over 200 patients. Customs separately seized 5,000 unapproved peptide units at the border.
FDA Warning Letters Target Marketers of Unapproved Weight Loss Drugs
The FDA published warning letters targeting companies marketing GLP-1 receptor agonists without regulatory approval, addressing CGMP violations and clinical trial protocol failures.
FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Takedown
The FDA announced steps to restrict compounded GLP-1 products, specifically naming Hims & Hers. Novo Nordisk has also sued Hims & Hers over compounded semaglutide.
HIMS Stock Gains as FDA Signals Lifting Peptide Compounding Restrictions
Hims & Hers Health stock rose on reports the FDA is preparing to allow compounding pharmacies to produce previously banned injectable peptides, potentially expanding the telehealth company's operations.
FDA Poised to Reverse 2023 Peptide Ban Following RFK Jr. Advocacy
Federal regulators are moving toward restoring legal access to injectable peptides barred from pharmacy compounding in 2023, which could redirect patients from unregulated online sellers to regulated pharmacy channels.
STAT News: FDA Peptide Compounding Shift and Iran Conflict Impact on Clinical Trials
STAT's pharmaceutical roundup covers the FDA's expected move to allow compounding of previously banned peptides and the impact of the Iran conflict on global clinical trial recruitment.
FDA Expected to Lift Peptide Compounding Ban at RFK Jr.'s Urging
The FDA is moving to allow compounding pharmacies to produce 14+ injectable peptides banned in 2023. Health Secretary RFK Jr. publicly backed the reversal, while top FDA leaders reportedly have reservations about politically-driven decisions.
FDA Warns 30 Telehealth Companies Over Compounded GLP-1 Marketing
The FDA issued warning letters to 30 telehealth firms for false or misleading claims about compounded GLP-1 weight-loss products, signaling a major crackdown on illegal online marketing.
Wellness World Eagerly Awaits FDA Peptide Reclassification
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Experts Warn About Safety Risks of Unproven Peptides as FDA Reversal Looms
Eric Topol of Scripps Research called peptide data "woefully minuscule," warning about impurities, random dosing, and dangerous stacking of unproven compounds from gray-market sources.
AP Investigation: Unapproved Peptide Injections Promoted by Influencers
In-depth AP investigation on influencers and celebrities promoting unapproved injectable peptides produced by compounding pharmacies without FDA-level scrutiny.
FDA Peptide Reclassification 2026: What It Means for Patients
Analyzes the announcement that ~14 of 19 peptides on FDA's Category 2 list will move back to Category 1, restoring access through licensed compounding pharmacies with a prescription.
Compounding Pharmacy Industry Responds to FDA Crackdown on GLP-1 Drugs
APC CEO Scott Brunner discusses the regulatory landscape for compounded GLP-1 receptor agonists amid increasing scrutiny and legal battles over compounded peptide drugs.
Sherwood News: Peptide Gold Rush as Deregulation Triggers Industry Scramble
Companies are rushing to upgrade from gray-market research-grade to medical-grade peptide standards to supply doctors' offices as deregulation approaches.